205
Participants
Start Date
March 31, 2012
Primary Completion Date
July 31, 2013
Study Completion Date
July 31, 2013
lebrikizumab
subcutaneous dose every 4 weeks
lebrikizumab
subcutaneous dose every 4 weeks
lebrikizumab
subcutaneous dose every 4 weeks
placebo
subcutaneous dose every 4 weeks
Brisbane
North Syracuse
Pittsburgh
Altoona
Hershey
Sellersville
Philadelphia
Baltimore
Fairfax
Columbia
Greenville
Decatur
Woodstock
Columbus
Panama City
Miami
Kissimmee
Toledo
Canton
Cincinnati
Centerville
Indianapolis
Lafayette
Ypsilanti
Novi
Bay City
Madison
Minneapolis
Plymouth
Missoula
Normal
Chesterfield
St Louis
Overland Park
Omaha
Oklahoma City
Tulsa
Houston
Sugar Land
Boerne
Austin
Austin
El Paso
Centennial
Colorado Springs
Twin Falls
Murray
Los Angeles
Long Beach
Orange
Redwood City
San Mateo
Stockton
Medford
Spokane
Oxford
Brockton
Brick
Edison
Ocean City
Teaneck
Verona
Pittsburgh
Lead Sponsor
Genentech, Inc.
INDUSTRY